Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Vistagen Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Vistagen Therapeutics, Inc.’s stock price such as:

• Vistagen Therapeutics, Inc.’s current stock price and volume
• Why Vistagen Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for VTGN from analysts
• VTGN’s stock price momentum as measured by its relative strength

About Vistagen Therapeutics, Inc. (VTGN)

Before we jump into Vistagen Therapeutics, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company’s product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase II clinical trial to treat major depressive disorder. It also develops PH80, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase II clinical trial for the treatment of vasomotor symptoms, including hot flashes due to menopause, premenstrual dysphoric disorder, and other women’s health disorders; PH15, an investigational pherine nasal spray, which is in Phase II clinical trial for the treatment to improve cognitive impairment caused by mental fatigue and potentially other disorders; PH284, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase II clinical trial to treat loss of appetite associated with chronic disorders, such as cancer or heart disease, as well as cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain for treating depression and neurological disorders. In addition, the company’s clinical-stage pipeline consists of intranasal product candidates comprising pherines. It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders. Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

Want to learn more about Vistagen Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Vistagen Therapeutics, Inc..

Vistagen Therapeutics, Inc.’s Stock Price as of Market Close

As of March 10, 2026, 1:48 PM, CST, Vistagen Therapeutics, Inc.’s stock price was $0.622.

Vistagen Therapeutics, Inc. is up 1.06% from its previous closing price of $0.615.

During the last market session, Vistagen Therapeutics, Inc.’s stock traded between $0.602 and $0.630. Currently, there are approximately 42.23 million shares outstanding for Vistagen Therapeutics, Inc..

Vistagen Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Vistagen Therapeutics, Inc. Stock Price History

Vistagen Therapeutics, Inc.’s (VTGN) price is currently up 6.06% so far this month.

During the month of March, Vistagen Therapeutics, Inc.’s stock price has reached a high of $0.650 and a low of $0.560.

Over the last year, Vistagen Therapeutics, Inc. has hit prices as high as $5.140 and as low as $0.430. Year to date, Vistagen Therapeutics, Inc.’s stock is down 6.1%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Vistagen Therapeutics, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of March 09, 2026, there were 0 analysts who downgraded Vistagen Therapeutics, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Vistagen Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Vistagen Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Vistagen Therapeutics, Inc.’s current valuation based on AAII’s Value Grade is a C, which means it is considered to be Average.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Vistagen Therapeutics, Inc. (VTGN) by visiting AAII Stock Evaluator.

Relative Price Strength of Vistagen Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of March 09, 2026, Vistagen Therapeutics, Inc. has a weighted four-quarter relative price strength of -27.00%, which translates to a Momentum Score of 6 and is considered to be Very Weak.

Want to learn more about how Vistagen Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Vistagen Therapeutics, Inc. Stock Price: Bottom Line

As of March 10, 2026, Vistagen Therapeutics, Inc.’s stock price is $0.622, which is up 1.06% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Vistagen Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.